FY2025 · ended Dec 31, 2025 · Revenue $3.31M, +142.7% YoY · Filed Mar 30, 2026
Nuo Therapeutics, Inc. (AURX) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $3.3 million and a net loss of $2.5 million. Free cash flow was -$1.1 million. As of Jun 30, 2026 it held $449,325 in cash and investments and $60,090 in total debt.
Revenue (TTM)
$5.20M
+166.6% vs year-ago TTM
Net income (TTM)
$-2.01M
+18.5% vs year-ago TTM
Operating cash flow (TTM)
$-2.15M
-201.2% vs year-ago TTM
Free cash flow (TTM)
$-2.45M
-123.2% vs year-ago TTM
EPS
$-0.03
+57.1% vs prior year
Dividend per share
None
Shares outstanding
48.29M
+3.1% vs prior year
Net cash
$389,235
as of Jun 30, 2026
Operating margin
-33.3%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- AURX (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1091596
- Former names
- Nuo Therapeutics, Inc (until Dec 23, 2014); CYTOMEDIX INC (until Oct 8, 2014); AUTOLOGOUS WOUND THERAPY INC (until Apr 10, 2000); AUTOLOGOUS WOUND TRERAPY INC (until Mar 23, 2000)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $3.3M | $1.4M | $608,525 | $112,250 | $0 |
| Operating income | -$2.5M | -$2.5M | -$3.2M | -$3.3M | -$90,670 |
| Net income | -$2.5M | -$2.3M | -$3.2M | -$3.2M | -$90,670 |
| Diluted EPS | — | — | — | — | -$0.03 |
| Operating cash flow | -$864,971 | -$2.2M | -$3.2M | -$3.7M | -$119,955 |
| Free cash flow | -$1.1M | -$2.4M | -$3.2M | -$3.8M | -$119,955 |
| Total assets | $1.8M | $1.2M | $1.9M | $3.0M | $1.5M |
| Total liabilities | $2.8M | $675,796 | $838,732 | $856,022 | $673,079 |
| Stockholders' equity | -$956,559 | $513,712 | $1.0M | $2.2M | $792,839 |
| Cash and investments | $548,946 | $283,714 | $928,681 | $2.1M | $1.4M |
| Total debt | $97,346 | $164,206 | $255,592 | $335,045 | $0 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Oct 6, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 17, 2026 | Aug 17, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Jun 3, 2026 | May 29, 2026 |
| 8-K |
Current report
Results of operations
|
May 14, 2026 | May 14, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
All 1001 Nuo Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.